CN105246882A - BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 - Google Patents
BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 Download PDFInfo
- Publication number
- CN105246882A CN105246882A CN201480015733.0A CN201480015733A CN105246882A CN 105246882 A CN105246882 A CN 105246882A CN 201480015733 A CN201480015733 A CN 201480015733A CN 105246882 A CN105246882 A CN 105246882A
- Authority
- CN
- China
- Prior art keywords
- bcl
- compound
- alkyl
- cancer
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910634742.2A CN110302205B (zh) | 2013-01-16 | 2014-01-15 | BCL-2/Bcl-xL抑制剂的医药用途及其药物组合物 |
| CN201910634723.XA CN110305162A (zh) | 2013-01-16 | 2014-01-15 | BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753066P | 2013-01-16 | 2013-01-16 | |
| US61/753066 | 2013-01-16 | ||
| PCT/US2014/011571 WO2014113413A1 (en) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910634723.XA Division CN110305162A (zh) | 2013-01-16 | 2014-01-15 | BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 |
| CN201910634742.2A Division CN110302205B (zh) | 2013-01-16 | 2014-01-15 | BCL-2/Bcl-xL抑制剂的医药用途及其药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105246882A true CN105246882A (zh) | 2016-01-13 |
Family
ID=51165292
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910634742.2A Active CN110302205B (zh) | 2013-01-16 | 2014-01-15 | BCL-2/Bcl-xL抑制剂的医药用途及其药物组合物 |
| CN201910634723.XA Pending CN110305162A (zh) | 2013-01-16 | 2014-01-15 | BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 |
| CN201480015733.0A Pending CN105246882A (zh) | 2013-01-16 | 2014-01-15 | BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910634742.2A Active CN110302205B (zh) | 2013-01-16 | 2014-01-15 | BCL-2/Bcl-xL抑制剂的医药用途及其药物组合物 |
| CN201910634723.XA Pending CN110305162A (zh) | 2013-01-16 | 2014-01-15 | BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9096625B2 (enExample) |
| EP (2) | EP2945940B1 (enExample) |
| JP (1) | JP6347793B2 (enExample) |
| KR (2) | KR102210316B1 (enExample) |
| CN (3) | CN110302205B (enExample) |
| AU (1) | AU2014207716B2 (enExample) |
| CA (1) | CA2897055C (enExample) |
| ES (1) | ES2819232T3 (enExample) |
| HK (1) | HK1219734A1 (enExample) |
| NZ (1) | NZ709635A (enExample) |
| SG (1) | SG11201505525UA (enExample) |
| WO (1) | WO2014113413A1 (enExample) |
| ZA (1) | ZA201504902B (enExample) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177955A (zh) * | 2016-08-18 | 2016-12-07 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN109152933A (zh) * | 2016-04-21 | 2019-01-04 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| CN110662752A (zh) * | 2018-04-30 | 2020-01-07 | 尤尼蒂生物技术公司 | 用于临床管理由衰老细胞引起或介导的病症以及治疗癌症的Bcl家族拮抗剂磷杂环化合物 |
| CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| CN111374943A (zh) * | 2018-12-28 | 2020-07-07 | 苏州亚盛药业有限公司 | 药物组合物及其制备方法 |
| CN111410650A (zh) * | 2019-01-04 | 2020-07-14 | 苏州亚盛药业有限公司 | 制备磺胺类药物的方法 |
| CN112168830A (zh) * | 2019-07-02 | 2021-01-05 | 苏州亚盛药业有限公司 | 一种含有mTOR抑制剂的药物组合及其应用 |
| CN112294966A (zh) * | 2019-07-31 | 2021-02-02 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途 |
| CN112469696A (zh) * | 2018-06-13 | 2021-03-09 | 联合生物科技股份有限公司 | 供在由衰老细胞引起或介导的状况的临床管理中使用和用于治疗癌症的作为Bcl家族拮抗剂的酰基磺胺 |
| CN112707900A (zh) * | 2019-10-24 | 2021-04-27 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CN113018446A (zh) * | 2018-07-31 | 2021-06-25 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂与化疗药物的组合及其应用 |
| CN113350281A (zh) * | 2020-03-02 | 2021-09-07 | 苏州亚盛药业有限公司 | 载药聚合物胶束及其制剂和制备方法 |
| CN113929715A (zh) * | 2020-07-13 | 2022-01-14 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂化合物或其盐的结晶形式或无定形形式 |
| WO2022022706A1 (en) * | 2020-07-31 | 2022-02-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating lung diseases |
| CN114096256A (zh) * | 2019-05-13 | 2022-02-25 | 苏州亚盛药业有限公司 | 用于预测bcl-2/bcl-xl抑制剂对癌症的功效的方法和组合物 |
| WO2022111647A1 (en) * | 2020-11-27 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof |
| US11478469B2 (en) | 2018-07-31 | 2022-10-25 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| US11491167B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| US11554127B2 (en) | 2018-07-31 | 2023-01-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| WO2023011488A1 (zh) * | 2021-08-02 | 2023-02-09 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| US12118414B2 (en) | 2018-01-22 | 2024-10-15 | Bioventures, Llc | BCL-2 proteins degraders for cancer treatment |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014113413A1 (en) * | 2013-01-16 | 2014-07-24 | The Regents Of The University Of Michigan | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| EP3708170A1 (en) | 2014-05-05 | 2020-09-16 | BioVentures, LLC | Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents |
| EP3177144A4 (en) | 2014-07-22 | 2018-01-24 | Bioventures, LLC. | Compositions and methods for selectively depleting senescent cells |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| WO2017101851A1 (en) * | 2015-12-18 | 2017-06-22 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| NZ757763A (en) | 2016-03-28 | 2025-07-25 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
| WO2019033122A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| EP4234025A3 (en) | 2017-08-11 | 2024-04-24 | Unity Biotechnology, Inc. | Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| AU2018357829B2 (en) | 2017-12-30 | 2019-09-26 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| SG11202005985PA (en) | 2018-01-10 | 2020-07-29 | Recurium Ip Holdings Llc | Benzamide compounds |
| FI3788042T3 (fi) | 2018-04-29 | 2025-04-07 | Beigene Switzerland Gmbh | Bcl-2-inhibiittoreita |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US11491168B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof |
| WO2020041406A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| TWI729662B (zh) * | 2019-01-04 | 2021-06-01 | 大陸商蘇州亞盛藥業有限公司 | 一種磺胺類化合物及製備磺胺類化合物的製程 |
| US20220372042A1 (en) | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| TWI885019B (zh) | 2019-11-27 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物 |
| WO2021110136A1 (en) * | 2019-12-04 | 2021-06-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
| CN114786654A (zh) * | 2019-12-11 | 2022-07-22 | 密执安大学评议会 | 用于全身递送Bcl-2和Bcl-xL拮抗剂的组合物和方法 |
| EP3914257B1 (en) * | 2020-04-10 | 2023-12-27 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of a bcl-2/bcl-xl inhibitor with osimertinib |
| TW202200574A (zh) | 2020-04-15 | 2022-01-01 | 英屬開曼群島商百濟神州有限公司 | Bcl-2抑制劑 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| US20230270816A1 (en) | 2020-07-06 | 2023-08-31 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| CA3199345A1 (en) * | 2020-11-10 | 2022-05-19 | Unity Biotechnology, Inc. | Crystalline solid meglumine salt inhibitor of bcl and methods of making and using same |
| US12454674B2 (en) | 2020-12-04 | 2025-10-28 | University Of Notre Dame Du Lac | Method of encapsulating single cells utilizing an alternating current electrospray |
| TW202415653A (zh) * | 2022-08-02 | 2024-04-16 | 大陸商北京星奇原生物科技有限公司 | Ｂｃｌ－ｘｌ降解化合物 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| WO2024245312A1 (en) * | 2023-05-30 | 2024-12-05 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| AU2005277223C1 (en) | 2004-08-20 | 2009-05-21 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof |
| KR101533268B1 (ko) | 2005-05-12 | 2015-07-03 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
| JP2009515997A (ja) | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| JP5277168B2 (ja) * | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| HRP20120577T1 (hr) | 2008-07-24 | 2012-08-31 | Nerviano Medical Sciences S.R.L. | 3,4-diarilpirazoli kao inhibitori proteinskih kinaza |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| AU2012209295B2 (en) | 2011-01-25 | 2016-06-30 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
| WO2014113413A1 (en) * | 2013-01-16 | 2014-07-24 | The Regents Of The University Of Michigan | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
-
2014
- 2014-01-15 WO PCT/US2014/011571 patent/WO2014113413A1/en not_active Ceased
- 2014-01-15 KR KR1020157021823A patent/KR102210316B1/ko active Active
- 2014-01-15 CA CA2897055A patent/CA2897055C/en active Active
- 2014-01-15 EP EP14741180.5A patent/EP2945940B1/en active Active
- 2014-01-15 US US14/155,809 patent/US9096625B2/en active Active
- 2014-01-15 EP EP20163914.3A patent/EP3689886A1/en not_active Withdrawn
- 2014-01-15 NZ NZ70963514A patent/NZ709635A/en unknown
- 2014-01-15 HK HK16107756.1A patent/HK1219734A1/zh unknown
- 2014-01-15 CN CN201910634742.2A patent/CN110302205B/zh active Active
- 2014-01-15 ES ES14741180T patent/ES2819232T3/es active Active
- 2014-01-15 SG SG11201505525UA patent/SG11201505525UA/en unknown
- 2014-01-15 JP JP2015553788A patent/JP6347793B2/ja active Active
- 2014-01-15 AU AU2014207716A patent/AU2014207716B2/en active Active
- 2014-01-15 CN CN201910634723.XA patent/CN110305162A/zh active Pending
- 2014-01-15 CN CN201480015733.0A patent/CN105246882A/zh active Pending
- 2014-01-15 KR KR1020207037597A patent/KR102318204B1/ko active Active
-
2015
- 2015-07-08 ZA ZA2015/04902A patent/ZA201504902B/en unknown
- 2015-08-03 US US14/816,191 patent/US9403856B2/en active Active
Non-Patent Citations (3)
| Title |
|---|
| HAIBIN ZHOU ET.AL.: "Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity", 《J. MED. CHEM.》 * |
| JARKKO RAUTIO ET.AL.: "Prodrugs: design and clinical applications", 《NAT URE REVIEWS | DRUG DISCOVERY》 * |
| JIANFANG CHEN ET.AL.: "Structure-Based Discovery of BM-957 as a Potent Small-Molecule Inhibitor of Bcl‑2 and Bcl-xL Capable of Achieving Complete Tumor Regression", 《J. MED. CHEM.》 * |
Cited By (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109152933A (zh) * | 2016-04-21 | 2019-01-04 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| US11319316B2 (en) | 2016-04-21 | 2022-05-03 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
| CN109152933B (zh) * | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN106177955A (zh) * | 2016-08-18 | 2016-12-07 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| US12118414B2 (en) | 2018-01-22 | 2024-10-15 | Bioventures, Llc | BCL-2 proteins degraders for cancer treatment |
| CN112513057A (zh) * | 2018-04-30 | 2021-03-16 | 联合生物科技公司 | 供在由衰老细胞引起或介导的状况的临床管理中使用和用于治疗癌症的作为Bcl家族拮抗剂的酰基氨基膦酸酯和酰基苄胺 |
| CN110662752A (zh) * | 2018-04-30 | 2020-01-07 | 尤尼蒂生物技术公司 | 用于临床管理由衰老细胞引起或介导的病症以及治疗癌症的Bcl家族拮抗剂磷杂环化合物 |
| CN112513057B (zh) * | 2018-04-30 | 2024-01-05 | 联合生物科技公司 | 供在由衰老细胞引起或介导的状况的临床管理中使用和用于治疗癌症的作为Bcl家族拮抗剂的酰基氨基膦酸酯和酰基苄胺 |
| CN112469696A (zh) * | 2018-06-13 | 2021-03-09 | 联合生物科技股份有限公司 | 供在由衰老细胞引起或介导的状况的临床管理中使用和用于治疗癌症的作为Bcl家族拮抗剂的酰基磺胺 |
| US11554127B2 (en) | 2018-07-31 | 2023-01-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| CN113018446A (zh) * | 2018-07-31 | 2021-06-25 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂与化疗药物的组合及其应用 |
| US11491167B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| US11478470B2 (en) | 2018-07-31 | 2022-10-25 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| US11478469B2 (en) | 2018-07-31 | 2022-10-25 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| CN111374943B (zh) * | 2018-12-28 | 2021-09-03 | 苏州亚盛药业有限公司 | 药物组合物及其制备方法 |
| CN111374943A (zh) * | 2018-12-28 | 2020-07-07 | 苏州亚盛药业有限公司 | 药物组合物及其制备方法 |
| CN111410650A (zh) * | 2019-01-04 | 2020-07-14 | 苏州亚盛药业有限公司 | 制备磺胺类药物的方法 |
| US11414400B2 (en) | 2019-01-04 | 2022-08-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing sulfonamides drugs |
| CN114096256A (zh) * | 2019-05-13 | 2022-02-25 | 苏州亚盛药业有限公司 | 用于预测bcl-2/bcl-xl抑制剂对癌症的功效的方法和组合物 |
| CN112168830A (zh) * | 2019-07-02 | 2021-01-05 | 苏州亚盛药业有限公司 | 一种含有mTOR抑制剂的药物组合及其应用 |
| CN112168830B (zh) * | 2019-07-02 | 2022-01-25 | 苏州亚盛药业有限公司 | 一种含有mTOR抑制剂的药物组合及其应用 |
| CN112294966A (zh) * | 2019-07-31 | 2021-02-02 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途 |
| CN112294966B (zh) * | 2019-07-31 | 2021-12-17 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途 |
| CN112707900B (zh) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CN112707900A (zh) * | 2019-10-24 | 2021-04-27 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CN113350281B (zh) * | 2020-03-02 | 2023-08-15 | 苏州亚盛药业有限公司 | 载药聚合物胶束及其制剂和制备方法 |
| CN113350281A (zh) * | 2020-03-02 | 2021-09-07 | 苏州亚盛药业有限公司 | 载药聚合物胶束及其制剂和制备方法 |
| WO2022012481A1 (en) * | 2020-07-13 | 2022-01-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystalline or Amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts |
| CN113929715A (zh) * | 2020-07-13 | 2022-01-14 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂化合物或其盐的结晶形式或无定形形式 |
| WO2022022706A1 (en) * | 2020-07-31 | 2022-02-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating lung diseases |
| WO2022111647A1 (en) * | 2020-11-27 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof |
| WO2023011488A1 (zh) * | 2021-08-02 | 2023-02-09 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| US9096625B2 (en) | 2015-08-04 |
| CA2897055A1 (en) | 2014-07-24 |
| HK1219734A1 (zh) | 2017-04-13 |
| AU2014207716A1 (en) | 2015-07-23 |
| KR102210316B1 (ko) | 2021-01-29 |
| NZ709635A (en) | 2019-10-25 |
| CN110302205B (zh) | 2020-06-09 |
| CN110305162A (zh) | 2019-10-08 |
| US9403856B2 (en) | 2016-08-02 |
| KR20210002126A (ko) | 2021-01-06 |
| ZA201504902B (en) | 2016-07-27 |
| JP2016506916A (ja) | 2016-03-07 |
| EP2945940A1 (en) | 2015-11-25 |
| SG11201505525UA (en) | 2015-08-28 |
| EP2945940B1 (en) | 2020-07-15 |
| AU2014207716B2 (en) | 2017-07-27 |
| JP6347793B2 (ja) | 2018-06-27 |
| US20150336994A1 (en) | 2015-11-26 |
| ES2819232T3 (es) | 2021-04-15 |
| CN110302205A (zh) | 2019-10-08 |
| US20140199234A1 (en) | 2014-07-17 |
| WO2014113413A1 (en) | 2014-07-24 |
| KR20150104631A (ko) | 2015-09-15 |
| EP2945940A4 (en) | 2016-07-06 |
| EP3689886A1 (en) | 2020-08-05 |
| CA2897055C (en) | 2021-04-20 |
| KR102318204B1 (ko) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110302205B (zh) | BCL-2/Bcl-xL抑制剂的医药用途及其药物组合物 | |
| JP5998152B2 (ja) | Ｂｃｌ−２／ｂｃｌ−ｘｌ阻害剤およびそれを使用する治療方法 | |
| JP6247298B2 (ja) | Ｉａｐタンパク質の二価阻害薬およびそれを用いた治療方法 | |
| AU2012209295A1 (en) | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | |
| CN102317290A (zh) | Stat3抑制剂及使用stat3抑制剂的治疗方法 | |
| HK40025523A (en) | Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer | |
| HK40008278A (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same | |
| HK40008279A (en) | Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof | |
| HK40008279B (en) | Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof | |
| NZ613504B2 (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1219734 Country of ref document: HK |
|
| CB02 | Change of applicant information |
Address after: michigan Applicant after: The Regents of the Univ. of Michigan Address before: Michigan Applicant before: The Regents of The Univ. of Michigan |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160113 |
|
| RJ01 | Rejection of invention patent application after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1219734 Country of ref document: HK |